Company intelligence / Profile preview

Leyden Labs

Ownership: Private
Development stage: Phase 1

Overview

Leyden Labs is advancing intranasal antibody programs, including PanFlu candidate CR9114 which has entered Phase 1 clinical trials for influenza prophylaxis. The company has published data confirming the potential of its intranasal antibody approach.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodiesBispecific antibodiesIntranasal antibody formulations
Industry: Biotech

Drug pipeline

1 asset

CR9114

Unknown

Partnerships

Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

Beyond the preview

Go deeper on Leyden Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leyden Labs.

Explore the full profile